CADL
Candel Therapeutics, Inc.NASDAQHealthcare$5.00+0.40%ClosedMarket Cap: $274.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.31
P/S
0.00
EV/EBITDA
-3.33
DCF Value
$2.20
FCF Yield
-14.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.4%
ROA
-30.5%
ROIC
-41.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-15.8M | $-29.5M | $-0.54 | — |
| FY 2025 | $0.00 | -Infinity% | $-48.3M | $-38.2M | $-0.72 | — |
| Q3 2025 | $0.00 | -Infinity% | $-13.2M | $-11.3M | $-0.21 | — |
| Q2 2025 | $0.00 | -Infinity% | $-11.2M | $-4.8M | $-0.09 | — |
| Q1 2025 | $0.00 | -Infinity% | $-8.1M | $7.4M | $0.23 | — |
| Q4 2024 | $0.00 | -Infinity% | $-8.1M | $-14.1M | $-0.40 | — |
| FY 2024 | $0.00 | -Infinity% | $-33.4M | $-55.2M | $-1.74 | — |
| Q3 2024 | $0.00 | -Infinity% | $-8.8M | $-10.6M | $-0.33 | — |
| Q2 2024 | $0.00 | -Infinity% | $-8.6M | $-22.2M | $-0.74 | — |
| Q1 2024 | $0.00 | -Infinity% | $-7.9M | $-8.2M | $-0.28 | — |
| Q4 2023 | $0.00 | -Infinity% | $-10.3M | $-11.1M | $-0.38 | — |
| FY 2023 | $0.00 | -Infinity% | $-38.4M | $-37.9M | $-1.31 | — |